Literature DB >> 24435045

Clinical course of asymptomatic adult moyamoya disease.

Kyung-Il Jo1, Je Young Yeon, Seung-Chyul Hong, Jong-Soo Kim.   

Abstract

BACKGROUND: As regular medical check-ups are becoming more common, the prevalence of asymptomatic moyamoya disease (MMD) is increasing. However, the definition and clinical features are still unclear. The lack of precision has hampered the establishment of guidelines for the management of asymptomatic MMD. The purpose of this study was to define and clarify the clinical characteristics of asymptomatic MMD in adults.
METHODS: We identified all adults (aged ≥18 years) with MMD who underwent digital subtraction angiography or magnetic resonance angiography at our institution from 1995 through 2010. The authors defined asymptomatic MMD as asymptomatic or nonspecific symptom without any infarction or ischemia on magnetic resonance imaging. In our MMD registry, 40 patients (74 hemispheres) were identified and enrolled in this retrospective cohort study. Their demographic, radiological and clinical findings were evaluated. The log-rank test was used to assess prognostic factors. Pearson's correlation test and the Mann-Whitney U test were used to identify correlation angiographic staging and age or perfusion status.
RESULTS: Overall, 6 patients underwent indirect bypass surgery and 36 received antiplatelet medication. On initial single positron emission tomography (35 patients, 67 affected hemispheres), basal and acetazolamide stress brain perfusion were decreased in 19 (28.4%) and 22 (32.8%) hemispheres, respectively. Among 70 angiographically evaluated hemispheres, 6 were unilateral MMD; 27 of 64 affected hemispheres (42.2%) had transdural collateral at evaluation. Age (p = 0.309, Pearson's correlation test) and hemodynamic impairment (p = 0.614, Mann-Whitney U test) did not correlate with angiographic staging. During a median 32-month (range 6-203) clinical follow-up, 3 nonsurgically treated patients had a transient ischemic attack, which was associated with decreased vascular reserve (p < 0.001, log-rank test) and smoking (p = 0.017). Other variables did not show a significant association with clinical progression. During a median 24-month (range 12-108) radiological follow-up, 3 patients displayed angiographic progression and 3 displayed new hemodynamic abnormalities. Radiological progressions were related to hypertension only (p = 0.022). In this case series, there was no case of ischemic or hemorrhagic stroke.
CONCLUSION: The findings suggest that asymptomatic MMD in adults is not a stable disease in our definition. However, stroke rate (0%) was lower than previous reports. Lifestyle modification, stroke risk factor control and/or antiplatelet medication seem to be appropriate initial treatments for patients with normal cerebrovascular reserve. A clear definition of asymptomatic MMD and further clarification of its clinical course are needed to set precise treatment guidelines.

Entities:  

Mesh:

Year:  2014        PMID: 24435045     DOI: 10.1159/000356350

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  9 in total

Review 1.  Surgical Treatment of Adult Moyamoya Disease.

Authors:  Si Un Lee; Chang Wan Oh; O-Ki Kwon; Jae Seung Bang; Seung Pil Ban; Hyoung Soo Byoun; Tackeun Kim
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

Review 2.  Basal and Acetazolamide Brain Perfusion SPECT in Internal Carotid Artery Stenosis.

Authors:  Teck Huat Wong; Qaid Ahmed Shagera; Hyun Gee Ryoo; Seunggyun Ha; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2020-01-08

3.  Long-term mortality in patients with moyamoya angiopathy according to stroke presentation type in South Korea.

Authors:  Sang-Hyuk Im; Dong-Kyu Jang; Hoon Kim; Sang-Kyu Park; Kyung-Do Han
Journal:  Acta Neurochir (Wien)       Date:  2021-08-24       Impact factor: 2.216

4.  Clinicoepidemiological features of asymptomatic moyamoya disease in adult patients.

Authors:  Jeyul Yang; Joo Chul Hong; Chang Wan Oh; O-Ki Kwon; Gyojun Hwang; Jeong Eun Kim; Hyun-Seung Kang; Won-Sang Cho; Tackeun Kim; Jong Un Moon; Seong Yeol Ahn; Jun Hak Kim; Jae Seung Bang
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2014-09-30

Review 5.  Moyamoya Disease: Epidemiology, Clinical Features, and Diagnosis.

Authors:  Jong S Kim
Journal:  J Stroke       Date:  2016-01-29       Impact factor: 6.967

6.  Pathophysiological Significance of Neutrophilic Transfer RNA-Derived Small RNAs in Asymptomatic Moyamoya Disease.

Authors:  Lingzhi Li; Ping Liu; Rongliang Wang; Yuyou Huang; Jichang Luo; Liqun Jiao; Zhen Tao; Yangmin Zheng; Junfen Fan; Haiping Zhao; Ziping Han; Yumin Luo
Journal:  Cells       Date:  2021-05-01       Impact factor: 6.600

7.  Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study).

Authors:  Daisuke Onozuka; Akihito Hagihara; Kunihiro Nishimura; Akiko Kada; Jyoji Nakagawara; Kuniaki Ogasawara; Junichi Ono; Yoshiaki Shiokawa; Toru Aruga; Shigeru Miyachi; Izumi Nagata; Kazunori Toyoda; Shinya Matsuda; Akifumi Suzuki; Hiroharu Kataoka; Fumiaki Nakamura; Satoru Kamitani; Ataru Nishimura; Ryota Kurogi; Tetsuro Sayama; Koji Iihara
Journal:  BMJ Open       Date:  2016-03-15       Impact factor: 2.692

8.  The Efficacy of Surgical Treatment for the Secondary Prevention of Stroke in Symptomatic Moyamoya Disease: A Meta-Analysis.

Authors:  Cong Qian; Xiaobo Yu; Jianru Li; Jingyin Chen; Lin Wang; Gao Chen
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

Review 9.  A critical appraisal of bypass surgery in moyamoya disease.

Authors:  Michael Moussouttas; Igor Rybinnik
Journal:  Ther Adv Neurol Disord       Date:  2020-05-26       Impact factor: 6.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.